Logo image of CAPR

CAPRICOR THERAPEUTICS INC (CAPR) Stock Fundamental Analysis

NASDAQ:CAPR - US14070B3096 - Common Stock

7.1 USD
+0.08 (+1.21%)
Last: 8/22/2025, 8:00:02 PM
7.1 USD
0 (0%)
After Hours: 8/22/2025, 8:00:02 PM
Fundamental Rating

4

CAPR gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 549 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CAPR as it has an excellent financial health rating, but there are worries on the profitability. CAPR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CAPR had negative earnings in the past year.
CAPR had a negative operating cash flow in the past year.
CAPR had negative earnings in each of the past 5 years.
CAPR had negative operating cash flow in 4 of the past 5 years.
CAPR Yearly Net Income VS EBIT VS OCF VS FCFCAPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

CAPR has a Return On Assets of -52.39%. This is comparable to the rest of the industry: CAPR outperforms 47.91% of its industry peers.
Looking at the Return On Equity, with a value of -66.66%, CAPR is in line with its industry, outperforming 57.38% of the companies in the same industry.
Industry RankSector Rank
ROA -52.39%
ROE -66.66%
ROIC N/A
ROA(3y)-39.87%
ROA(5y)-41.5%
ROE(3y)-124.19%
ROE(5y)-96.97%
ROIC(3y)N/A
ROIC(5y)N/A
CAPR Yearly ROA, ROE, ROICCAPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CAPR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CAPR Yearly Profit, Operating, Gross MarginsCAPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

CAPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CAPR has been increased compared to 1 year ago.
CAPR has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CAPR has an improved debt to assets ratio.
CAPR Yearly Shares OutstandingCAPR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CAPR Yearly Total Debt VS Total AssetsCAPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 3.26 indicates that CAPR is not in any danger for bankruptcy at the moment.
CAPR has a Altman-Z score of 3.26. This is in the better half of the industry: CAPR outperforms 73.95% of its industry peers.
There is no outstanding debt for CAPR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.26
ROIC/WACCN/A
WACC9.75%
CAPR Yearly LT Debt VS Equity VS FCFCAPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 4.37 indicates that CAPR has no problem at all paying its short term obligations.
The Current ratio of CAPR (4.37) is comparable to the rest of the industry.
A Quick Ratio of 4.37 indicates that CAPR has no problem at all paying its short term obligations.
With a Quick ratio value of 4.37, CAPR perfoms like the industry average, outperforming 49.91% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.37
Quick Ratio 4.37
CAPR Yearly Current Assets VS Current LiabilitesCAPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for CAPR have decreased strongly by -76.34% in the last year.
CAPR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -50.69%.
The Revenue has been growing by 85.64% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-76.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-62.86%
Revenue 1Y (TTM)-50.69%
Revenue growth 3Y352.73%
Revenue growth 5Y85.64%
Sales Q2Q%-100%

3.2 Future

CAPR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.40% yearly.
CAPR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 75.86% yearly.
EPS Next Y19.25%
EPS Next 2Y31.82%
EPS Next 3Y32.24%
EPS Next 5Y27.4%
Revenue Next Year51.25%
Revenue Next 2Y154.47%
Revenue Next 3Y84.91%
Revenue Next 5Y75.86%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
CAPR Yearly Revenue VS EstimatesCAPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
CAPR Yearly EPS VS EstimatesCAPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CAPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CAPR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CAPR Price Earnings VS Forward Price EarningsCAPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CAPR Per share dataCAPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

CAPR's earnings are expected to grow with 32.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.82%
EPS Next 3Y32.24%

More info and screens

0

5. Dividend

5.1 Amount

CAPR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CAPRICOR THERAPEUTICS INC

NASDAQ:CAPR (8/22/2025, 8:00:02 PM)

After market: 7.1 0 (0%)

7.1

+0.08 (+1.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-11 2025-11-11
Inst Owners41.08%
Inst Owner Change-26.1%
Ins Owners1.16%
Ins Owner Change0.25%
Market Cap324.61M
Analysts83.75
Price Target21.01 (195.92%)
Short Float %29.19%
Short Ratio4.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-41.63%
Min EPS beat(2)-64.08%
Max EPS beat(2)-19.18%
EPS beat(4)1
Avg EPS beat(4)-11.7%
Min EPS beat(4)-64.08%
Max EPS beat(4)40.43%
EPS beat(8)4
Avg EPS beat(8)-14.71%
EPS beat(12)8
Avg EPS beat(12)-5.96%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)-36.44%
Min Revenue beat(4)-100%
Max Revenue beat(4)92.08%
Revenue beat(8)4
Avg Revenue beat(8)-10.81%
Revenue beat(12)8
Avg Revenue beat(12)1660.07%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-51.1%
PT rev (3m)-52.88%
EPS NQ rev (1m)-1.38%
EPS NQ rev (3m)-33.33%
EPS NY rev (1m)0%
EPS NY rev (3m)-98.74%
Revenue NQ rev (1m)-61.1%
Revenue NQ rev (3m)-80.78%
Revenue NY rev (1m)-79.01%
Revenue NY rev (3m)-34.98%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 24.24
P/FCF N/A
P/OCF N/A
P/B 3.09
P/tB 3.09
EV/EBITDA N/A
EPS(TTM)-1.64
EYN/A
EPS(NY)-0.31
Fwd EYN/A
FCF(TTM)-1.23
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS0.29
BVpS2.3
TBVpS2.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -52.39%
ROE -66.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.87%
ROA(5y)-41.5%
ROE(3y)-124.19%
ROE(5y)-96.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 207.77%
Cap/Sales 25.27%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.37
Quick Ratio 4.37
Altman-Z 3.26
F-Score4
WACC9.75%
ROIC/WACCN/A
Cap/Depr(3y)311.17%
Cap/Depr(5y)361.27%
Cap/Sales(3y)48.94%
Cap/Sales(5y)164.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-76.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-62.86%
EPS Next Y19.25%
EPS Next 2Y31.82%
EPS Next 3Y32.24%
EPS Next 5Y27.4%
Revenue 1Y (TTM)-50.69%
Revenue growth 3Y352.73%
Revenue growth 5Y85.64%
Sales Q2Q%-100%
Revenue Next Year51.25%
Revenue Next 2Y154.47%
Revenue Next 3Y84.91%
Revenue Next 5Y75.86%
EBIT growth 1Y-144.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-121.58%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-171.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-197.89%
OCF growth 3YN/A
OCF growth 5YN/A